跳至主要内容
临床试验/NCT02846298
NCT02846298进行中(未招募)不适用

Evaluation of Pharmacokinetic / Pharmacodynamic Data and Interest Individualized Therapeutic Drug Monitoring Glycopeptides and β-lactam-aminoglycoside ICU

Fondation Hôpital Saint-Joseph1 个研究点 分布在 1 个国家目标入组 172 人开始时间: 2015年11月8日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
172
试验地点
1
主要终点
Assessment of Pharmacodynamic Glycopeptides Cmax

研究概览

简要总结

Since the discovery of streptomycin in 1944, aminoglycosides retain a remarkable bactericidal activity vis-à-vis including aerobic gram-negative bacilli. Thus, their synergistic effect with beta-lactams and their rapid bactericidal on many make unavoidable pathogens and make it a cornerstone of the treatment of patients with severe sepsis or state of septic shock.

This is antibiotics exclusively parenteral administration. Their effectiveness is concentration-dependent and are administered by 30-minute infusion. Tolerance of venous is usually excellent. Their potential nephrotoxicity or cochleovestibular toxicity requires accurate monitoring of antibiotic residuals.

Moreover the fact that the effectiveness of the aminoglycosides is concentration dependent, the rate at the peak is decisive. A first sub-therapeutic dose leads to adaptively resistant bacteria compared to the aminoglycoside and therefore an increase of Minimal Inhibitory Concentrations (MIC). Many studies have been conducted in patients hospitalized in intensive care, highlighting underdoses in aminoglycosides when the prescribed dosages consistent with those used in non reanimated patients. Dr Moore showed in 89 ICU patients with bacteremia gram-negative bacilli, the relationship between the clinical course and obtaining whether therapeutic levels during the first administration of aminoglycosides. Thus, mortality in patients whose antibiotic concentrations to peak were subtherapeutic, amounted to 20.9% against 2.4% when concentrations were within the therapeutic range. In the context or an initial peak in the PK / PD ( Pharmacokinetic / Pharmacodynamic) objectives namely Cmax / MIC ≥ 8-10 desirable, individualized therapeutic drug monitoring and identification of factors that may cause a concentration of antibiotic at sub-therapeutic peak seems necessary , in patients for the majority an increased volume of distribution.

In addition to the β-lactams and glycopeptides, due to the increased volume of distribution in critically ill patients in sepsis, evaluation of serum 24 hours after starting treatment to check that the PK / PD goals for these molecules is achieved.

详细描述

Primary / secondary objective

Investigators propose to conduct a study with the goal:

  • Evaluate the rate of patients for whom efficacy endpoint PK / PD Cmax / MIC ≥ 8-10 is reached at the first dose of the usual doses.

  • Compare the 30-day mortality among patients with subclinical a first rate versus those who have reached the desired peak

  • Evaluate the rate of patients for whom PK / PD efficiency target for related antibiotics is reached:

  • Serum residual> 4X MIC for the β-lactam rate and continuous function of β-lactam and the germ.

  • Serum between 25 and 35 mg / L vancomycin continuously.

  • Assess the factors associated with obtaining a rate of aminoglycoside subtherapeutic peak in a population of critically ill patients.

  • Assess the residual to 12h after injection to an anticipation of residual dosed at 24.

Methodology :

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age w< 18 years old
  • admitted in ICU unit for whom aminoglycoside treatment for severe infection was prescribed

排除标准

  • Age less than 18 years
  • Treatment with aminoglycoside off label
  • Patient non hospitalized in intensive care

结局指标

主要结局

Assessment of Pharmacodynamic Glycopeptides Cmax

时间窗: 30 minutes after first injection

Evaluate the rate of patients for whom the objective of efficiency PK / PD Cmax / MIC ≥ 8-10 is reached at the first dose of the usual doses

Assessment of Pharmacokinetic Glycopeptides Cmax

时间窗: 30 minutes after first injection

Evaluate the rate of patients for whom the objective of efficiency PK / PD Cmax / MIC ≥ 8-10 is reached at the first dose of the usual doses

Assessment of Pharmacokinetic β-lactam-aminoglycoside Cmax

时间窗: 30 minutes after first injection

Evaluate the rate of patients for whom the objective of efficiency PK / PD Cmax / MIC ≥ 8-10 is reached at the first dose of the usual doses

Assessment of Pharmacodynamic β-lactam-aminoglycoside Cmax

时间窗: 30 minutes after first injection

Evaluate the rate of patients for whom the objective of efficiency PK / PD Cmax / MIC ≥ 8-10 is reached at the first dose of the usual doses

次要结局

  • Mortality rate(Day 30)
  • Assess the residual of β-lactam-aminoglycoside(Hour 12 and Hour 24 after injection)
  • Assess the residual of Glycopeptides(Hour 12 and Hour 24 after injection)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验